PROMINENT and AD-RIDDLE, two projects focusing on Alzheimer’s disease, are channelling health economics to ensure that new therapies and diagnostic methods for Alzheimer’s disease can be effectively implemented.

Our first Research Insights session will take place on 22 April from 14.00 to 16.00 CET and address the what, why and how of data sharing in dementia research, illustrating practical approaches, platf...

In this interview we talk with Dr Ini Umoh, a medical doctor and health economist with a strong commitment to advancing access to health innovations that improve patient outcomes and […]

PROMINENT will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities. The overriding…

On 23 February, the European Commission’s Innovation Radar published the PROMINENT innovation “Patient-centered diagnostic summary reports for dementi

As we begin 2026, the PROMINENT project continues to advance across all areas, with teams working intensively to deliver on key objectives. The prediction models and diagnostic algorithms team (Work [...

On 21 November 2025, members of the PROMINENT consortium convened in Stockholm (Sweden) and online for their third consortium meeting. The event brought together partners from across the project to […...

As we approach the end of 2025, partners among the PROMINENT project are happy to look back at great progress. Data sharing scaled across the consortium. Most partners delivered datasets […]

In this interview we talk with Dr Ini Umoh, a medical doctor and health economist with a strong commitment to advancing access to health innovations that improve patient outcomes and […]

At the EDDU we have a catalogue of iPSC lines from healthy individuals and from patients with neurological disorders.

In this spotlight on early-career researchers, Lena Sannemann from the University Hospital Cologne shares how Public Involvement (PI) is shaping the development…

PROMINENT will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities. The overriding…

PROMINENT and AD-RIDDLE, two projects focusing on Alzheimer’s disease, are channelling health economics to ensure that new therapies and diagnostic methods for Alzheimer’s disease can be effectively i...

Background Multimodal prediction models for Alzheimer's disease (AD) are emerging as promising tools for improving detection and informing prognosis. Obje...

At AD/PD 2025, Makrina Daniilidou presented research on how cardiovascular and metabolic comorbidities affect the performance of blood-based biomarkers in Alzheimer’s disease diagnosis. We spoke with ...

On 28 March 2025, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the marketing authorisation application of Eli […]